Beijing’s 2010 Biopharmaceutical Sales Reach RMB 55.95 Billion
This article was originally published in PharmAsia News
Beijing's biopharmaceutical sales reached RMB 55.95 billion in 2010, RMB 48.35 billion for product sales and RMB 7.6 billion from R&D services, according to the recent Beijing Biopharmaceutical Industry Development Project (G20 Project)'s 2010 conference
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.